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TCTAP A-075
Prognostic Signiﬁcance of Anemia in Patients Undergoing PCI with First and
Second Generation DES (Katowice Registry)
Wojciech Wojakowski1, Wojciech Wanha1, Aleksandra Pluta1, Kamil Marcinkiewicz1,
Jan Dola1, Damian Kawecki2, Beata Morawiac2, Lukasz Krzych1, Andrzej Ochala1,
Michal Tendera1
1Medical University of Silesia, Katowice, Poland, 2Medical University of Silesia,
Zabrze, Poland
Background: Anemia present prior to PCI is associated with an increased risk of
death, myocardial infarction (MI) and bleeding complications in particular in acute
coronary syndromes (ACS). Patients with anemia often do not receive recommended
by guidelines antithrombotic treatment and drug-eluting stents (DES) because of the
increased bleeding risk. Aim of this all-comer Katowice Registry is to compare 1-year
outcomes in patients with coronary artery disease (CAD) and anemia treated with PCI
with ﬁrst and second-generation DES.
Methods: We enrolled 1916 consecutive patients (65% males, mean age 63 y) pre-
senting with unstable angina (78%), NSTEMI (15%) and STEMI/LBBB MI (7%)
treated either with ﬁrst (paclitaxel, sirolimus) or second generation (everolimus,
zotarolimus, biolimus A9) DES (o-DES 34%; n-DES¼66%). Anemia was deﬁned
according to WHO [hemoglobin (Hb) level <13g/dL for men and <12g/dL for
women]. Incidence of MACCE (death, MI, stroke, repeat-revascularization) at 1-year
was a primary end-point of this study and was evaluated by telephone follow-up or
data from national ministry of health.
Results: The study population was stratiﬁed according to presence of anemia on
admission. Anemia was present in 11% of patients (microcytic 11%, normocytic 53%,
macrocytic 35%). Patients with anemia were older (6710 vs. 6210 years,
p<0.001), had diabetes (44% vs. 6%,p¼0,02), chronic kidney disease (32% vs. 15%,
p<0,001), PAD (17% vs. 10%, p¼0,005), carotid disease (10% vs. 5%, p¼0,006),
history of MI (57% vs. 46%,p¼0,002), CABG (31% vs. 19%,p¼0,0001), impaired
LEF (50 (40-57)% vs. 55 (45-60)%,p¼<0,001), higher GRACE score [>140 (75%
vs. 53%,p¼0,010) and more frequently had bleeding requiring transfusion (3,2% vs.
0,5%, p<0,001). Hospitalization was longer [5 (4-7) vs. 4 (3-6) days,p¼0,002]. Pa-
tients with anemia had more 3 vessel disease (36,4% vs. 26,1%,p¼0,001) and higher
SYNTAX [21(12-27) pkt. vs. 14(8-22) pkt. p¼0,001)]. Stent thrombosis in culprit
vessel was signiﬁcantly more frequent (1,7% vs. 0,3%, p¼0,037). In 1-year F-U there
was signiﬁcantly higher mortality (7,4% vs. 2,9%, p¼0,001) than in pts without
anemia. In patients treated with o-DES there was a trend to higher rate of CABG
during F-U (4,1% vs. 0,7%, p¼0,082). Univariate regression showed that anemia was
a predictive of death, however in multivariate regression model only eGFR, LVEF and
age, but not anemia (HR 1,23 95%CI 0,56-1,91) were independent predictors of death.
Despite higher disease burden in patients with anemia 1-year follow-up showed that
there was no difference in composite MACCE (death, MI, stroke, repeat-revascular-
ization) in comparison to patients with normal Hb (p¼0,60, Kaplan-Meyer). There
was also no difference according to type of DES (ﬁrst vs. new generation).
Conclusion: Anemia is relatively frequent (11%) in patients with CAD and associated
with higher 1-year mortality. Despite higher bleeding risk use of DES is safe to the
same extent as in patients without anemia.
TCTAP A-076
Urinary L-FABP Predicts Survival Outcome Before Contrast Agent
Administration in Patients with Chronic Kidney Disease
Kenichi Manabe, Hiroshi Kamihata, Masayuki Motohiro, Takeshi Senoo,
Susumu Yoshida, Shigeo Umemura, Satoshi Tsujimoto, Ichiro Shiojima
Kansai Medical University, Hirakata City, Japan
Background: Preexisting renal insufﬁciency was independent risk factors for
contrast-induced acute kidney injury (CI-AKI). One of the associated predisposing
factors for CI-AKI is a propensity for enhanced renal hypoxia. Urinary L-FABP levels
correlated well to the level of renal ischemia. Therefore, we believe increased levels of
urinary L-FABP relate to the presence of a preexisting renal ischemia in patients
undergoing contrast administration. The purpose of the present study was to examine
the clinical signiﬁcance of urinary L-FABP levels before contrast agent administration
in patients with chronic kidney disease (CKD).
Methods: We performed a retrospective study of 215 patients with CKD who
underwent elective catheterization [serum creatinine (Cr) 1.1mg /dl]. Serum Cr and
L-FABP levels were measured immediately before contrast agent administration.
Patients were prospectively followed during a median follow-up period of 755 days
with the end points of Cardiac Cerebral death. CI-AKI was deﬁned as an increase of
0.3 mg/dl (26.5micromol/l) within 2 days of contrast media exposure.
Results: CI-AKI developed in 22 patients (10.2%). High L-FABP levels group
( deﬁned as more than 24.5 microg ⁄ g Cr) was 45 patients and CI-AKI in high L-FABPS22 JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstractlevels group developed in 11patients. A total of 18 cardiac cerebral deaths occurred
during a follow-up period and survival outcome tended to be worse high L-FABP
levels group. (15.9% vs 6.5% P value: 0.045) Kaplan-Meier analysis clearly demon-
strated that patients with high L-FABP levels group were higher rate of cardiac ce-
rebral deaths than those with low L-FABP levels group. (Log rank test:P value:
0.0259).
Conclusion: Urinary L-FABP provides an important information for predicting
CI-AKI and survival outcome before contrast agent administration. These data indi-
cate that urinary L-FABP level is a novel promising marker to provide useful prog-
nostic information for clinical outcomes in patients with chronic kidney disease.
TCTAP A-077
IVUS Guided Minimum Contrast PCI for CKD Patients
Yoshifumi Hano, Nakamura Shigeru, Tomoko Kobayashi, Atsushi Funatsu,
Masahiro Mizobuchi, Hideaki Takahashi, Munemitsu Otagaki, Satoru Sasaki
Kyoto Katsura Hospital, kyoto, Japan
Background: Estimated safety dose of contrast media for chronic kidney dis-
ease(CKD) patients is computed by the following formula,bodyweight x5/Serum
creatinine(SCr). To reduce the account of contrast media, IVUS guidance throughout
the procedure, would be effective.
Methods: To clarify the efﬁcacy of IVUS guided minimum contrast PCI(MC-PCI) for
CKD patients. From January 2008 to September 2013, consecutive 54 patients of 73
lesions were treated with MC-PCI. Patients with SCr/1.5mg/dl who required elec-
tive PCI based on diagnostic angiogram were enrolled in this study. Hemodialysis
patients were excluded.During PCI, operators manipulated wires without contrast
referring the previous cineangiogram and checked the IVUS. PCI was performed
according with IVUS ﬁndings alone. At the end of the procedure, angiogram was done
with minimal account of contrast media. Contrast induced nephropathy CIN was
diagnosed if SCr level was increased by 0.5 mg/dl within 48 hours.
Results: 45 lesions were treated with stent and 28 lesions were treated with balloon.
Used contrast dose at PCI was signiﬁcantly lower than that of diagnostic CAG
(13.8ml9.2ml VS 39.627.3ml P<0.0001). One case was treated with contrastfree
procedure. Used contrast dose at PCI was 9.36.5% of estimated safety dose. Though,
SCr after 48 hrs showed no increase compared to that of the base line (Pre vs Post
2.10.6 vs 2.10.8 P¼0.438). CIN was found in 2 cases(4%).
Conclusion: IVUS guided MC-PCI minimize CIN in CKD patients. It is comparable
results to that of patients normal renal function.
TCTAP A-078
Serum Homocysteine Level Inﬂuences on Risk Factor and Severity of Coronary
Artery Disease in Young Patients
Zhu Hang, Xue Hao, Zhang Ming, Chen Si, Wang Guang yi
Chinese People’s Liberation Army General Hospital, Beijing, China
Background: To explore the association between serum homocysteine (Hcy) level
and risk Factor in young patients with coronary heart disease.
Methods: A total of 1455 coronary heart disease patients [(502.4) years, 868male]
hospitalized in our department between June 2011 and March 2013 were included in
this prospective study. Patients were divided into young Coronary heart disease group
(age40, n¼455) and Non youth Coronary heart disease group (age>40, n¼400).
Their serum homocysteine was measured by High Performance Liquid Chromatog-
raphy method.
Results: The serum HCY, TG level of CHD group in young CAD groups were all
higher than those of Non youth CAD groups (P<0.01 or P<0.05), the CAD with
passed history of hypertension and Type-II diabetes of young CHD groups were all
lower than those Non youth group (P<0.01 or P<0.05). The Logistic regression
analysis demonstrated that HCY and history of young CAD were all independent risk
factors for young CHD patients (P<0.01 or P<0.05), while hypertension and diabetes
mellitus were all independent risk factors for Non youth CHD patients (P<0.05).
Conclusion: Higher serum homocysteine is an independent for young CAD patients.Innovative Devices and Futuristic Therapies
(TCTAP A-079 to TCTAP A-080)
TCTAP A-079
Clinical Efﬁcacy and Safety of Bioresorbable Vascular Scaffold in an Unselected
Patient Population: A Single Centre Real World Experience
Min Er Ching, Hee Hwa Ho, Yau Wei Ooi, Ko Beng, Julian Tan, Kwok Kong Loh,
Nwe Tun Yin, Fahim Haider Jafary, Paul Jau Lueng Ong
Tan Tock Seng Hospital, Singapore, Singapore
Background: The novel drug-eluting bioresorbable vascular scaffold (BVS) is a
revolutionary treatment option for obstructive coronary artery disease in percutaneouss/ORAL/High Risk Patients: Diabetes, Heart Failure, Renal Failure, Others
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contemporary clinical registries. We evaluated the safety and efﬁcacy of BVS in our
unselected South-east Asian patients and report on the clinical outcomes.
Methods: Between May 2012 to October 2013, 79 patients (83.5 % male, mean age
52  10 years) with 83 coronary lesions were treated with a total of 116 BVS. The
primary endpoint was in-hospital major adverse cardiac events (MACE) ie a com-
posite of cardiovascular death, target vessel related myocardial infarction (MI) and
target lesion revascularization (TLR). Secondary endpoints included individual
components of MACE and scaffold thrombosis at 6 months follow up.
Results: The majority of patients presented with acute coronary syndrome (50.6 %).
Transradial PCI was performed in 98 % of cases. Intracoronary imaging and cutting
balloons were used as adjunctive PCI tool in 46 % and 52 % of cases respectively. The
mean number of BVS implanted per patient was 1.4  0.7, mean BVS diameter was
3.1  0.3 mm and total BVS length was 30  19 mm.
BVS was implanted in de novo lesions in 95 % of cases with the left anterior
descending artery being the most common target vessel (52%). 4 BVS were implanted
in non de novo lesions (1 saphenous vein graft, 1 left internal mammary artery and 2
instent restenosis).
There was no MACE observed in-hospital. However, there were 2 cases of subacute
scaffold thrombosis within 30 days of PCI which required re-intervention. There were
no further ischaemic events at 6 months follow-up.
Conclusion: Early experience with BVS in our unselected South-east Asian patients
reveals a promising result with a low incidence of ischaemic events. Longer clinical
follow-up is necessary to prove its long term efﬁcacy and safety.
TCTAP A-080
Patient-speciﬁc Cardiovascular Models for Educational and Training Purposes
Ashok Ilankovan1, Peter Verschueren2
1Materialise Malaysia, Kuala Lumpur, Malaysia, 2Materialise NV, Leuven, Belgium
Background: Structural heart defects affect 8 out of 1000 newborns and while a large
percentage of these defects have no serious consequences for the child’s life, some patients
present life-threatening conditions that need to be carefully understood and treated.
Multiple techniques are applied in the manufacturing of heart models used for educa-
tional purposes. Nevertheless, these models are often generic representations of the
anatomy and do not account for an array of conﬁgurations that congenital cases present.
3D printing offers an adaptable and powerful alternative in creating accurate pa-
tient-speciﬁc models for educational purposes and pre-surgical planning.
Methods: CT and MRI scans of a number of cardiovascular pathologies were ob-
tained. The anatomies were then reconstructed and modiﬁed in 3D so that they could
be successfully 3D printed. Multiple 3D printing techniques and materials were then
utilized to produce physical anatomical representations of the cardiac anatomy,
according to the speciﬁc needs of each case.
Results: Rigid models of the lumen were obtained for educational and communication
purposes, where each cardiac structure was represented in a different color for better
understanding of the patient’s pathologies.
Flexible, translucent hollow models of the congenital heart defects were 3D printed
for the simulation of the intended procedure, aimed at offering better insight to the
surgical outcome.
Conclusion: 3D printed patient-speciﬁc models of the cardiovascular anatomy from
medical image data hold great promise to improving clinical understanding of congenital
heart defects, offering physicians superior training and planning possibilities.Invasive Coronary Imaging: IVUS, OCT,
Spectroscopy, and Other
(TCTAP A-081 to TCTAP A-086)
TCTAP A-081
Efﬁcacy of the Combination Catheter; Intravascular Ultrasound(IVUS)
with a Balloon
Shozo Ishihara, Chasu Ku, Hiroyoshi Nishiyama, Teson Yann, Tasuku Kozasa
Mimihara General Hospital, Osaka, Japan
Background: VIBE RX catheter is the world’s ﬁrst catheter that combines intra-
vascular ultrasound (IVUS) with a balloon in one device. We evaluated the efﬁcacy of
the novel catheter.
Methods: 50 patients who underwent percutaneous coronary intervention (PCI) in our
hospital between July 2012 and October 2012 were enrolled in this study. They were
randomly divided into two groups: using IVUS with a balloon (n¼25), and using
ordinary IVUS (n¼25). Patients with distal lesions, chronic total occlusion (CTO) and
acute myocardial infarction (AMI) were excluded. We assessed procedure time,
ﬂuoroscopy time, contrast volume, the device crossability.
Results: Procedure time were 67.7+-24.7 minutes in VIBE group and 79.1+-23.3
minutes in EagleEye group (p¼0.06). Fluoroscopy time were 20.7+-10.5 minutes in
VIBE group and 25.5+-11.7 minutes in EagleEye group (p¼0.11). Contrast volumeJACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORAwere 120.2+-34.8ml in VIBE group and 119.9+-34.1ml in EagleEye group (p¼0.81).
3 patients in both groups had difﬁculties of the device crossability.
Conclusion: Our study suggests that using VIBE RX catheter may contribute to
reduce procedure time and ﬂuoroscopy time. Further studies about the economic ef-
ﬁcacy and the usefulness for more complex situations are needed.
TCTAP A-082
Optical Frequency Domain Imaging Guidance for Coronary Stent Implantation
in Comparison with Intra Ultrasound Guidance
Tomoko Kobayashi, Satoru Sasaki, Munemitsu Otagaki, Hideaki Takahashi,
Yoshifui Hano, Masahiro Mizobuchi, Atsushi Funatsu
Kyoto Katsura Hospital, Kyoto, Japan
Background: Intravascular ultrasound (IVUS) has been used as a guidance of
stenting. Optical Frequency Domain Imaging (OFDI) has high resolution and super-
imposed technology on cineangiogram. The aim of this study was to assess the
feasibility of OFDI-guided stent implantation.
Methods: Total of 25 de novo, consecutive, elective stenting lesions (22 patients)
were enrolled in this study. OFDI and IVUS images were recorded before interven-
tion. IVUS images were blinded for operators. Stent implantation was performed
under OFDI-guidance alone. IVUS conﬁrmation was performed after the procedure
and further treatment was permitted based on IVUS results. One-month after the
procedures, strategy of stent deployment was re-built by the same operator with the
IVUS record before intervention.
Results: Selected stent length and diameter were equal between OFDI-guidance and
IVUS-guidance (O;23.8mm vs I;23.3mm,p¼0.53, O;3.38mm vs I;3.33mm,p¼0.41).
The selected landing point difference of OFDI-guidance and IVUS-guidance were
1.8mm at proximal edge and 0.8mm at distal edge. Distal protection device was
deployed 4 cases according to OFDI images. Additional inﬂation was performed after
ﬁnal IVUS in 2 cases. There was no complication (perforation, slow-ﬂow/no-ﬂow,
dissection to need additional stenting) during procedure and no in-hospital MACE
(death, QMI/nonQMI, subacute stent thrombosis).
Conclusion: OFDI-guidance is comparable to IVUS-guidance for elective stent
implantation.
TCTAP A-083
Impact of Diabetes on Heavily Calciﬁed Plaque in Extremely Late In-stent
Restenosis Lesions After Bare-metal Stent Implantation
Takahiro Watanabe, Kazuhiko Yumoto, Yoshiyasu Takeda, Yuichi Hanaki,
Yasutoshi Shinoda, Tatsuhiko Murase, Tagayasu Anzai, Tomoyuki Fukuzawa,
Yoshihisa Naruse, Seigen I, Jyunji Kawagoe, Hajime Aoki, Shinya Kowase,
Kenji Kurosaki, Kenichi Katou
Yokohama Rousai, Yokohama, Japan
Background: In-stent neoatherosclerosis is a major concern of late in-stent restenosis
after either drug-eluting stent or BMS implantation. Patients with DM increase
requiring target lesion revascularization (TLR) at long-term follow-up. The charac-
teristics of lesions with extremely late in-stent restenosis after BMS implantation
remain unclear.
Methods: Median follow-up duration after BMS implantation was 10.02.8 years
(range 4-16 years). Consecutive 35 late in-stent restenosis lesions required the ﬁrst
TLR beyond 4 years after BMS implantation were estimated with IVUS measuring the
calcium arc and length.
Results: All patients (67.55 y.o.; 28 male) presented ischemic symptoms (18 ACS
included 5 STEMI, 17 stable ischemia). All in-stent lesions contained various calciﬁed
plaque. The mean calcium arc was 138100 degree and length 8.210 mm respec-
tively. In DM patients, calcium arc was signiﬁcantly greater than those of non-DM
(19583 vs 8379 degree; p<0.01). The rate of severely calciﬁed lesion deﬁned as
calcium arc over 180 degree was higher in DM than those in non-DM (63.1% vs
12.5%: p<0.01). There was no difference in the period between the index procedure
and TLR (DM 9.83.0 years, non DM 10.62.1 years).
Conclusion: Various calciﬁed plaque are contained in the late in-stent restenosis
lesions regardless of DM. However DM is correlated with heavily calciﬁed plaque
in the lesions with late in-stent restenosis. We should pay attention to treatment of
late in-stent restenosis with DM patients because of existence of heavily calciﬁed
plaque.
TCTAP A-084
Impact of Pre-dilatation Strategy on Vessel Response Following Stent
Implantation in Patients with De Novo Coronary Artery Lesion
Kazuyuki Maeda, Katsuhisa Waseda, Hiroaki Takashima, Masanobu Fujimoto,
Yasuo Kuroda, Takashi Kosaka, Akiyoshi Kurita, Hirohiko Ando, Soichiro Kumagai,
Shinichiro Sakurai, Daiki Kato, Akihiro Suzuki, Shigeko Sato, Tomofumi Mizuno,
Tetsuya Amano
Aichi Medical University, Nagakute, Japan
Background: Although follow-up event rates have signiﬁcantly improved since the
introduction of drug-eluting stents, pre-dilatation strategy before stenting is still
important to achieve better stent expansion. The Lacrosse non-slip element (NSE)L/Invasive Coronary Imaging: IVUS, OCT, Spectroscopy, and Other S23
